Noble Capital Markets Initiates Equity Research Coverage on Gyre Therapeutics (GYRE)
Noble Capital Markets (Noble), a full-service SEC / FINRA-registered broker-dealer dedicated exclusively to serving public and private middle market companies and their investors, has initiated equity research coverage on Gyre Therapeutics.
Noble’s Equity Research Analyst Robert LeBoyer launched coverage today with his report titled “Initiation of Coverage: Focused on Fibrosis” The full report can be viewed, at no cost, on Channelchek.com.
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of F351 (Hydronidone) for MASH-associated fibrosis in the U.S. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the PRC, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and F230.
About Noble Capital Markets
Established in 1984, Noble Capital Markets is an SEC / FINRA registered full-service investment bank and advisory firm with an award-winning research team and proprietary investor distribution platform. We deliver middle market expertise to entrepreneurs, corporations, financial sponsors, and investors. Over the past 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports.
About Channelchek
Noble launched www.channelchek.com in 2018 – an investor community dedicated exclusively to public emerging growth companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 7,000 public emerging growth companies are listed on the site, and content including equity research, webcasts, and industry articles.